Skip to main content
. 2021 Dec 17;82(4):632–647. doi: 10.1158/0008-5472.CAN-21-0373

Figure 7.

Figure 7. ILK loss enhances bosutinib and eCF506 treatment in vivo. A, Tumor growth rates for PX459v2 and ILK gRNA 2 tumors growing in immunodeficient Rag2-Il2rg double knockout mice (5 mice per group, 2 tumors per mouse) following treatment with vehicle, bosutinib (75 mg/kg), or eCF506 (40 mg/kg) given once daily via oral gavage. B, Final tumor volumes at day 35. C, Bosutinib and eCF506 inhibit pSrc in vivo as shown via Western blot analysis. D, Quantification of Western blots shown in C. E, Ki67 analysis using QuPath. ****, P < 0.0001, as determined by a two-way ANOVA with Bonferroni multiple comparisons correction. All error bars are SEM.

ILK loss enhances bosutinib and eCF506 treatment in vivo. A, Tumor growth rates for PX459v2 and ILK gRNA 2 tumors growing in immunodeficient Rag2-Il2rg double knockout mice (5 mice per group, 2 tumors per mouse) following treatment with vehicle, bosutinib (75 mg/kg), or eCF506 (40 mg/kg) given once daily via oral gavage. B, Final tumor volumes at day 35. C, Bosutinib and eCF506 inhibit pSrc in vivo as shown via Western blot analysis. D, Quantification of Western blots shown in C. E, Ki67 analysis using QuPath. ****, P < 0.0001, as determined by a two-way ANOVA with Bonferroni multiple comparisons correction. All error bars are SEM.